glp-1 patent Medicines Pool Executive Director Charles Gore tells Devex that one of his priorities in his last year on the job is to get a license for therapies. But he admits China patent expiry and new
Description
17 Albert SG, Wood EM, Ahir V

Share your info below and well reach out to schedule your visit

The limited duration and small sample size may have contributed to the lack of behavioral effects, and ongoing trials are exploring repeated dosing strategies (e.g., NCT06252623, NCT06691243)

More research is needed to fully understand their impact

they are looking for injunctions